What Patterns of Gastroparesis Are Reported with Ozempic?
Latest update (2026-01)
- FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]
From General Health Education to Targeted Pharmacovigilance
If you or someone you know has developed persistent nausea, vomiting, or bloating after starting Ozempic, you may be wondering whether gastroparesis could be the cause. Over decades of pharmacovigilance, delayed gastric emptying has been recognized as a rare but serious adverse effect of certain medications. This page examines patterns reported in medical literature linking Ozempic to gastroparesis and what the FDA warning says.
Clinical Evidence Linking Ozempic to Gastroparesis
Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes mellitus. Its prescribing information documents a range of gastrointestinal adverse reactions, which are among the most commonly reported side effects. Gastroparesis, a condition characterized by delayed gastric emptying in the absence of mechanical obstruction, has been associated with GLP-1 receptor agonists, including Ozempic, through clinical reports and mechanistic considerations. Clinical presentation of gastroparesis includes symptoms such as nausea, vomiting, early satiety, postprandial fullness, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy, breath tests, or wireless motility capsule studies. The condition can lead to nutritional deficiencies, weight loss, and impaired quality of life. In the context of Ozempic use, gastrointestinal symptoms are frequently reported, with nausea occurring in 15.8% of patients on 0.5 mg and 20.3% on 1 mg, compared to 6.1% on placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Vomiting was reported in 5.0% and 9.2% of patients on 0.5 mg and 1 mg, respectively, versus 2.3% on placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Diarrhea, abdominal pain, and constipation also occurred at higher rates in Ozempic-treated groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While these symptoms are common, they may overlap with gastroparesis presentation, raising the question of whether Ozempic can induce or exacerbate gastroparesis.
Mechanisms and Risk Considerations
The pharmacology of Ozempic involves activation of GLP-1 receptors, which slows gastric emptying and reduces postprandial glucose excursions. This mechanism is intended for glycemic control but can lead to delayed gastric emptying, a hallmark of gastroparesis. Mechanistic pathways linking Ozempic to gastroparesis include direct inhibition of antral contractions, relaxation of the gastric fundus, and modulation of vagal nerve activity. These effects can result in prolonged retention of gastric contents, contributing to symptoms such as nausea and vomiting. In clinical trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Risk considerations regarding the adequacy of warnings for Ozempic and gastroparesis are important. The prescribing information lists gastrointestinal adverse reactions, including nausea, vomiting, diarrhea, abdominal pain, and constipation, as common (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, gastroparesis is not explicitly listed as a warning or precaution. The label includes warnings for pancreatitis, diabetic retinopathy complications, hypoglycemia, acute kidney injury, hypersensitivity, and acute gallbladder disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The absence of a specific gastroparesis warning may leave patients and clinicians unaware of the potential for this serious condition.
Causation and Clinical Management
Causation-related considerations for affected patients involve establishing a temporal relationship between Ozempic initiation and symptom onset, excluding other causes of gastroparesis (e.g., diabetes itself, surgery, medications), and assessing symptom improvement upon drug discontinuation. The timeline between exposure and documented harm can vary; gastrointestinal symptoms often emerge during dose escalation, as noted in clinical trials (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, gastroparesis may develop after prolonged use, and symptoms may persist even after drug cessation in some cases. For patients experiencing persistent nausea, vomiting, or abdominal pain while on Ozempic, evaluation for gastroparesis is warranted. Clinicians should consider the drug's known effects on gastric emptying and weigh the risks and benefits of continued therapy. The FDA has received adverse event reports linking GLP-1 receptor agonists to gastroparesis, and ongoing surveillance is necessary to clarify the incidence and risk factors. In summary, while Ozempic's label documents gastrointestinal adverse reactions, the specific risk of gastroparesis may be underrecognized. Patients and healthcare providers should be vigilant for symptoms suggestive of delayed gastric emptying and consider alternative treatments if gastroparesis is suspected. References: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the FDA warning about Ozempic and gastroparesis?
The FDA has received adverse event reports linking GLP-1 receptor agonists like Ozempic to gastroparesis. While the prescribing information lists gastrointestinal adverse reactions such as nausea and vomiting, gastroparesis is not explicitly listed as a warning or precaution. The label includes warnings for pancreatitis, diabetic retinopathy complications, hypoglycemia, acute kidney injury, hypersensitivity, and acute gallbladder disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).
How is causation between Ozempic and gastroparesis established?
Causation is established by documenting a temporal relationship between Ozempic initiation and symptom onset, excluding other causes of gastroparesis (e.g., diabetes, surgery, other medications), and assessing symptom improvement upon drug discontinuation. Gastrointestinal symptoms often emerge during dose escalation, but gastroparesis may develop after prolonged use and can persist even after stopping the drug.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
References
Request a Free Case Review
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.